WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets Comments close on FDA's generative AI device framework Solventum clears its Restrata matrix for use under V.A.C. negative pressure therapy Medtronic takes a CE mark for five conduction system pacing pacemakers Paradromics hands Siemens Healthineers the imaging workup for its brain implant Empyrean submits a 510(k) for Vektra, its robotic brachytherapy system Masimo clears AFib detection on the Radius VSM wearable monitor Sequel clears the twiist insulin pump for adults with type 2 diabetes FTC issues a second request on the MiMedx purchase of Sanara MedTech Labcorp pays $722M upfront for BioReference testing assets

IPO filing

Centinel Spine files for a $100M NYSE listing on $157M in revenue

MedDevice Startups Staff · Oct 7 · 2 min read · Via Renaissance Capital

Centinel Spine filed an S-1 on October 7 for a listing of up to $100 million on the New York Stock Exchange under the ticker CNTL. The West Chester, Pennsylvania company sells the prodisc platform, four cervical systems and one lumbar system that replace a disc rather than fuse the segment.

Revenue reached $157 million for the twelve months ended June 30. First half revenue was $85.2 million against $60.1 million a year earlier, and a $503,000 net loss became $10.2 million of net income. Morgan Stanley, Goldman Sachs, Piper Sandler, Canaccord Genuity and BTIG are joint bookrunners.

Most device makers reach the IPO window still losing money. Centinel arrives a week after Oura shelved its own offering, with 42 percent first half growth and net income behind it. The company dates to 2008, when Raymedica and Surgicraft merged, so the prodisc revenue took eighteen years to look like this.

Questions & Answers

How much is Centinel Spine raising in its IPO?

Centinel Spine filed an S-1 on October 7, 2026 for a listing of up to $100 million on the NYSE under the ticker CNTL. Morgan Stanley, Goldman Sachs, Piper Sandler, Canaccord Genuity and BTIG are joint bookrunners.

What is Centinel Spine's revenue?

Centinel Spine reported $157 million in revenue for the twelve months ended June 30, 2026. First half 2026 revenue was $85.2 million with $10.2 million of net income, against $60.1 million and a $503,000 net loss a year earlier.

What does Centinel Spine make?

Centinel Spine sells the prodisc platform of artificial discs, four cervical systems and one lumbar system, which replace a spinal disc instead of fusing the segment. The company is based in West Chester, Pennsylvania and was formed in 2008 from the merger of Raymedica and Surgicraft.

← Back to Startups